Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2020 · 42 positions · Total reported value $1.69B · Top-10 concentration 59.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2020 13F filing, Casdin Capital disclosed 42 equity positions with a combined reported value of $1.69B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2020 were NVTAQ ($273.64M), BPMC ($120.90M), FATE ($104.65M). By sector, the heaviest allocations are Health Care 50.2%, Industrials 3.2%. Versus the prior quarter, allocation shifted toward Other (+5.2pp) and away from Health Care (-2.4pp), Industrials (-2.8pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 78% of names.

The largest new positions opened in Q2 2020 were BNR ($46.75M), GBIO ($33.84M), ONC ($28.26M).

Of the 3 positions fully exited versus the prior quarter, the largest were GNMK ($13.86M), GILD ($13.08M), SAGE ($11.06M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2020)

  • BNR BURNING ROCK BIOTECH LTD · $46.75M
  • GBIO GENERATION BIO CO · $33.84M
  • ONC BEONE MEDICINES LTD · $28.26M
  • AMRSQ AMYRIS INC · $22.84M
  • ORIC ORIC PHARMACEUTICALS INC · $8.48M
  • LEGN LEGEND BIOTECH CORP SPONSORED ADS · $5.75M
  • ZYME ZYMEWORKS INC COM · $4.69M

Fully Exited (vs previous quarter)

  • GNMK GENMARK DIAGNOSTICS INC · prev qtr: $13.86M
  • GILD GILEAD SCIENCES INC · prev qtr: $13.08M
  • SAGE SAGE THERAPEUTICS INC · prev qtr: $11.06M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 50.2%
Other 46.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 9.03M $273.64M 16.19%
16.19%
Add
2 1.55M $120.90M 7.16%
7.16%
Hold
3 3.05M $104.65M 6.19%
6.19%
Add
4 530.00K $84.98M 5.03%
5.03%
Reduce
5 870.00K $84.06M 4.97%
4.97%
Reduce
6 550.00K $81.46M 4.82%
4.82%
Reduce
7 4.85M $79.29M 4.69%
4.69%
Add
8 1.10M $67.45M 3.99%
3.99%
Hold
9 1.07M $57.22M 3.39%
3.39%
Hold
10 4.69M $53.50M 3.17%
3.17%
Reduce
11 1.73M $46.75M 2.77%
2.77%
New
12 1.00M $45.30M 2.68%
2.68%
Hold
13 1.19M $42.28M 2.50%
2.50%
Reduce
14 1.33M $42.13M 2.49%
2.49%
Add
15 1.86M $38.94M 2.31%
2.31%
Add
16 713.12K $34.50M 2.04%
2.04%
Reduce
17 1.61M $33.84M 2.00%
2.00%
New
18 1.31M $31.68M 1.88%
1.88%
Reduce
19 980.00K $29.45M 1.74%
1.74%
Hold
20 150.00K $28.26M 1.67%
1.67%
New
21 625.00K $26.76M 1.58%
1.58%
Add
22 1.44M $26.36M 1.56%
1.56%
Add
23 1.08M $26.30M 1.56%
1.56%
Hold
24 3.35M $25.13M 1.49%
1.49%
Add
25 5.35M $22.84M 1.35%
1.35%
New
26 266.43K $19.58M 1.16%
1.16%
Hold
27 300.00K $18.94M 1.12%
1.12%
Hold
28 1.43M $18.90M 1.12%
1.12%
Add
29 190.00K $15.61M 0.92%
0.92%
Hold
30 1.46M $13.04M 0.77%
0.77%
Hold
31 1.85M $12.29M 0.73%
0.73%
Reduce
32 289.39K $12.20M 0.72%
0.72%
Hold
33 30.00K $11.11M 0.66%
0.66%
Hold
34 2.95M $10.56M 0.62%
0.62%
Add
35 1.65M $9.90M 0.59%
0.59%
Add
36 750.00K $9.46M 0.56%
0.56%
Reduce
37 251.51K $8.48M 0.50%
0.50%
New
38 135.00K $5.75M 0.34%
0.34%
New
39 75.00K $4.84M 0.29%
0.29%
Hold
40 130.00K $4.69M 0.28%
0.28%
New
41 65.00K $3.88M 0.23%
0.23%
Reduce
42 120.00K $2.86M 0.17%
0.17%
Hold

FAQ

What did Casdin Capital buy in 2020-Q2?

In its 2020-Q2 13F filing, Casdin Capital reported 42 equity positions worth $1.69B in aggregate; its largest disclosed positions were NVTAQ ($273.64M), BPMC ($120.90M), FATE ($104.65M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $1.69B of long equity holdings across 42 positions as of 2020-Q2. Top-10 holdings account for 59.6% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →